2023/24 Publications

Between 1st April 2023 - 31st March 2024, the following articles were published by researchers using the NIHR Sheffield Clinical Research Facility (CRF).

Prehospital early warning scores for adults with suspected sepsis: retrospective diagnostic cohort study (STH20280: PHEWS)

Efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: a randomised, controlled trial (STH19031: CEASE AF)

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (STH21104: GenOMICC)

Quality of recovery following childbirth: a prospective, multicentre cohort study (STH21138: ObsQoR)

A randomized, double-blind, placebo-controlled phase 2 study of intratympanic OTO-313 in patients with moderate to severe subjective tinnitus (STH21863: OTONOMY OTO)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study (STH20540: CITADEL-203)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study (STH20589: CITADEL-205)

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors (STH21015: Explorer 7)

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease (STH21731: OCTAVE)

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study (STH16263: HCV Research UK V1)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (STH21355: RECOVERY)

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines (STH21800: COM-COV2)

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial (STH22175: MODERNA BOOSTER)

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (STH19688: IONIS)

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study (STH21068: Raise & STH21113: Raise XT)

Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study (STH15729: BILAG BR)

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial (STH18431: BASIL-2)